{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:15Z","timestamp":1790199555993,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech, Inc","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI CCSG","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0740-8","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T17:03:41Z","timestamp":1571850221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab"],"prefix":"10.1136","volume":"7","author":[{"given":"Luciana","family":"Molinero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Maund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Fass\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"O\u2019Hear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leisha A.","family":"Emens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"740_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1200\/JOP.2017.022632","volume":"13","author":"VK Gadi","year":"2017","unstructured":"Gadi VK, Davidson NE. Practical approach to triple-negative breast Cancer. J Oncol Pract. 2017;13:293\u2013300.","journal-title":"J Oncol Pract"},{"key":"740_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-016-4080-9","volume":"161","author":"WD Brok den","year":"2017","unstructured":"den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161:549\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"740_CR3","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"740_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228\u201341.","journal-title":"Nat Rev Clin Oncol"},{"key":"740_CR5","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959\u201366.","journal-title":"J Clin Oncol"},{"key":"740_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","volume":"47","author":"A Cimino-Mathews","year":"2016","unstructured":"Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47:52\u201363.","journal-title":"Hum Pathol"},{"key":"740_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of Atezolizumab therapy for patients with metastatic triple-negative breast Cancer: a phase 1 study. JAMA Oncol. 2019;5:74\u201382.","journal-title":"JAMA Oncol."},{"key":"740_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"EJ Lipson","year":"2014","unstructured":"Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in Cancer treatment. Semin Oncol. 2015;42:587-600. 9. Herbst RS, Soria JC, Kowanetz M, fine GD, Hamid O, Gordon MS, et al. predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u20137.","journal-title":"Nature."},{"key":"740_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/PAI.0000000000000594","volume":"27","author":"B Vennapusa","year":"2019","unstructured":"Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, et al. Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for Atezolizumab. Appl Immunohistochem Mol Morphol. 2019;27:92\u2013100.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"740_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","volume":"26","author":"TD Wu","year":"2010","unstructured":"Wu TD, Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics. 2010;26:873\u201381.","journal-title":"Bioinformatics."},{"key":"740_CR11","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29.","journal-title":"Genome Biol"},{"key":"740_CR12","unstructured":"Molinero L, Li Y, Chang Q-W, Maund S, Berg M, Harrison J, et al. Immunogenomic evolution and atypical response to atezolizumab in a patient with metastatic triple-negative breast cancer (mTNBC) abstract #p68. 2017; SITC; national harbor, Maryland."},{"key":"740_CR13","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688\u201398.","journal-title":"Clin Cancer Res"},{"key":"740_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023\u201331.","journal-title":"Nat Biotechnol"},{"key":"740_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.","journal-title":"Genome Med"},{"key":"740_CR16","doi-asserted-by":"publisher","first-page":"e1005965","DOI":"10.1371\/journal.pcbi.1005965","volume":"14","author":"JX Sun","year":"2018","unstructured":"Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, et al. A computational approach to distinguish somatic vs germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018;14:e1005965.","journal-title":"PLoS Comput Biol"},{"key":"740_CR17","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.clbc.2017.08.008","volume":"18","author":"S Cid","year":"2018","unstructured":"Cid S, Eiro N, Fernandez B, Sanchez R, Andicoechea A, Fernandez-Muniz PI, et al. Prognostic influence of tumor Stroma on breast Cancer subtypes. Clin Breast Cancer. 2018;18:e123\u2013e33.","journal-title":"Clin Breast Cancer"},{"key":"740_CR18","doi-asserted-by":"publisher","first-page":"e28403","DOI":"10.1371\/journal.pone.0028403","volume":"6","author":"T Karn","year":"2011","unstructured":"Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One. 2011;6:e28403.","journal-title":"PLoS One"},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung Cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633\u201341.","journal-title":"J Clin Oncol"},{"key":"740_CR20","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet."},{"key":"740_CR21","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1186\/gb-2007-8-8-r157","volume":"8","author":"AE Teschendorff","year":"2007","unstructured":"Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007;8:R157.","journal-title":"Genome Biol"},{"key":"740_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3:436\u201343.","journal-title":"Cancer Immunol Res"},{"key":"740_CR23","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920\u20138.","journal-title":"Nat Med"},{"key":"740_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell. 2017;171:934\u201349 e16.","journal-title":"Cell."},{"key":"740_CR25","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jamaoncol.2017.2140","volume":"3","author":"T Karn","year":"2017","unstructured":"Karn T, Jiang T, Hatzis C, Sanger N, El-Balat A, Rody A, et al. Association between genomic metrics and immune infiltration in triple-negative breast Cancer. JAMA Oncol. 2017;3:1707\u201311.","journal-title":"JAMA Oncol."},{"key":"740_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u201329.","journal-title":"N Engl J Med"},{"issue":"3","key":"740_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","volume":"5","author":"Sylvia Adams","year":"2019","unstructured":"Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast Cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol. 2018. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2018.5152\n                    \n                  .","journal-title":"JAMA Oncology"},{"key":"740_CR28","doi-asserted-by":"crossref","unstructured":"Emens LA, Loi S, Rugo HS, Schneeweiss A, Di\u00e9ras V, Iwata H, et al. IMpassion130: efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-na\u00efve, locally advanced or metastatic triple-negative breast cancer abstract #GS1-04. 2018; SABCS; San Antonio, Texas.","DOI":"10.1158\/1538-7445.SABCS18-GS1-04"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0740-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0740-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0740-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:29Z","timestamp":1601055929000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0740-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0740-8","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with Good Clinical Practice and the Helsinki Declaration, and approved by the Johns Hopkins Medicine Institutional Review Board. The patient provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication has been obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LM, YL, C-WC, SM, MF, CO, and PH are employees of Genentech, Incorporated. LAE receives research funding from Genentech, Incorporated and Hoffman-La Roche, Incorporated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}